Lytix Biopharma AS (Euronext Growth Oslo:LYTIX) announced on Wednesday that it has received a Notice of Allowance from the United States Patent and Trademark Office for US Patent Application No. 18/598,719, titled 'Immune Checkpoint Inhibitor Combinations'.

The patent protects the use of LTX-315 in combination with PD-1 immune checkpoint inhibitors, strengthening the company's intellectual property portfolio.

This approval extends the effective patent life of LTX-315 in the United States, reinforcing Lytix Biopharma's market position in cancer immunotherapy. Similar patents have been granted in other jurisdictions.

LTX-315 is currently being evaluated in two Phase II clinical trials. The ATLAS-IT-05 trial investigates its combination with pembrolizumab in metastatic melanoma patients who have failed prior PD-1/PD-L1 treatment. The NeoLIPA trial at Oslo University Hospital examines its use with pembrolizumab in earlier-stage, resectable melanoma.